A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2) | NYU Langone Health

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Solid Tumors
Age: Between 18 years - 99 years
Gender: Male or Female

Other Inclusion Criteria:

1) All patients' cancer must have progressed after treatment with standard therapies or have no appropriate available therapies. 2) Patient must have measurable disease by RECIST 1.1. 3) Have available archival formalin-fixed paraffin-embedded block(s) containing tumor or at least 20 unstained slides containing tumor.

You may not be eligible for this study if the following are true:

1) Patients currently receiving other anticancer therapies. 2) A life-threatening (Grade 4) immune-mediated adverse event related to prior immunotherapy. 3) Known CNS involvement by malignant disease. 4) Treatment with antibiotics within 14 days prior to first dose of study drug.